NCT05564650 2025-12-08Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeThomas Jefferson UniversityPhase 1 Active not recruiting6 enrolled
NCT04086264 2025-08-14IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid LeukemiaAbbViePhase 1/2 Active not recruiting218 enrolled